Nasal polyps. Nasal polyp
Conditions
Interventions
Intervention 1: Recipient of systemic corticosteroid (prednisolone tablets at a dose of mg/kg, manufactured by Wellona Pharma, India) once daily for two weeks. Intervention 2: Control group: Placebo r
Sponsors
Birjand University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Up to 18 years old Diagnosis of chronic rhinosinusitis with nasal polyposis No kidney or vascular disorders No chemotherapy No radiation therapy Not having malignancy
Exclusion criteria
Exclusion criteria: Disease heterogeneity with recurrent exacerbations of acute rhinosinusitis Rhinosinusitis without polyposis Sinusitis associated with ciliary dyskinesia or cystic fibrosis-associated sinusitis Failure to take prescribed medication regularly Immunocompromised patients High blood pressure Pregnant or breastfeeding people Failure to attend for examination Having diabetes Having systemic diseases High body mass index Excessive increase in blood sugar after receiving corticosteroids
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative pain level. Timepoint: Effect of corticosteroids for three months after nasal polyp surgery. Method of measurement: VAS pain questionnaire.;The status of patients' nasal and sinus symptoms. Timepoint: Three months after nasal polyp surgery and corticosteroid use. Method of measurement: SNOT-22 questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMasoud Asghari
Birjand University of Medical Sciences
Outcome results
None listed